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osting by EAbstract A series of 2-oxo-azetidinyl-quinazolin-4(3H)-ones 5a–k have been synthesized from
Schiff bases 4a–k. Schiff bases were synthesized by condensation reaction of compound 3 with
substituted aromatic aldehydes. The benzoxazinone 2 was prepared by the cyclization reaction of
acid chloride 1 with 5-bromo anthranilic acid. Further reaction of benzoxazinone 2 with hydrazine
hydrate yielded compound 3. The structures of synthesized compounds were elucidated on the basis
of elemental analyses as well as IR and NMR spectral data. Schiff bases 4a–k and 2-azetidinones
5a–k were screened for antibacterial and antifungal activities in vitro. Compounds having chloro
and methoxy group exhibited good antimicrobial activity.
ª 2010 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The heterocyclic compounds have great importance in medic-
inal chemistry. One of the most important heterocycle is qui-
nazolinone possess wide spectrum of biological activities like
antibacterial (Nanda et al., 2007), antifungal (Grover and
Kini, 2006), anticonvulsant (Archana et al., 2004), anti-inﬂam-t.in (N.B. Patel), drjaymin@
y. Production and hosting by
Saud University.
lseviermatory (Kumar et al., 2007), antiviral (Saleh et al., 2002),
hypolipidemic (Kurogi et al., 1996), antitubercular (Mosaad
et al., 2004), CNS depressant (Jatav et al., 2008), antitumor
(Cao et al., 2005), analgesic (Alagarsamy et al., 2007), antima-
larial (Jiang et al., 2005) and antihistaminic (Alagarsamy et al.,
2000). The 2-azetidinone ring system, a common structural
feature of a number of wide spectrum b-lactam antibiotics,
including penicillins, cephalosporins, carbapenems, nocardic-
ins and monobactams, which have been widely used as chemo-
therapeutic agents to treat bacterial infections and microbial
diseases. The 2-azetidinone derivatives have been reported to
possess wide range of biological activities like antibacterial
(Sharma et al., 1998), antifungal (Halve et al., 2007), anti-
inﬂammatory (Gurupadayya et al., 2008), analgesic (Ishwar
Bhat et al., 2003), anticonvulsant (Rajasekaran andMurugesan,
2005), anticancer (Veinberg and Vorona, 2004), and antituber-
cular (Kagthara et al., 2000). Biocidal activities of Schiff bases
have been well established. These have been attributed to the
toxophoric C‚N linkage in them. Schiff base acquired broad
spectrum biological activities like antibacterial (Iqbal et al.,
404 N.B. Patel, J.C. Patel2007), antifungal (Mishra et al., 2005), anti-inﬂammatory
(Sharma et al., 2002), antiproliferative (Vicini et al., 2006),
antitubercular (Lourenco et al., 2007) and anticonvulsant
(Ragavendran et al., 2007).
Diclofenac is non-steroidal anti-inﬂammatory drug, often
used to treat chronic pain associated with cancer, particularly
if inﬂammation is also present. It has been found to be effective
against all strains of multi-drug resistant Escherichia coli.
Therefore, it may be suggested that diclofenac has the capacity
to treat uncomplicated urinary tract infections caused by E. coli
(Mazumdar et al., 2006). The diclofenac analogue compounds
possess very good antibacterial activity (Dutta et al., 2000). The
literature survey reveals that substitution of different heterocy-
clic moieties at 2nd or 3rd position of quinazolinone nucleus
modulates the activity. In the present work we have synthesized
some new derivatives of quinazolin-4(3H)-one of diclofenac
analogue, containing 2-azetidinone at 3rd position and 2-
[(2,6-dichlorophenyl)amino]benzyl unit from diclofenac at sec-
ond position of quinazolin-4(3H)-one. The potency of schiff
bases 4a–k as well as 2-azetidinones 5a–k were calculated
against bacterial and fungal stains, and compared with refer-
ence drugs with hope to get better antimicrobial agents.2. Experimental
2.1. General
Melting points were determined in one-end-open capillary
tubes on a Mel-Temp apparatus and are uncorrected. Infrared
(IR) absorption spectra were recorded on Perkin–Elmer RX-1
FTIR spectrometer using potassium bromide (KBr) pellet and
the wave numbers were given in cm1. The 1H NMR spectra
were recorded in deutero chloroform (CDCl3) on a Bruker
Avance II 400 NMR spectrometer (400 MHz). The 13C
NMR spectra were recorded in deutero chloroform (CDCl3)
on a Bruker Avance II 400 NMR spectrometer operating at
100 MHz. The chemical shifts are reported in part per million
(d ppm) using tetramethylsilane (TMS) as an internal stan-
dard. The microanalyses were performed on a Carlo Erba
1108 elemental analyzer. The purities of the compounds were
checked by thin layer chromatography (TLC) using ready-
made silica gel plates (Merck) and benzene:methanol (8:2) as
a solvent system. The spots were developed in an iodine cham-
ber and visualized under ultraviolet (UV) lamp. 2-[(2,6-Dichlo-
rophenyl)amino]phenyl acetyl chloride 1 was synthesized by
the literature procedure (Furniss et al., 1989).
2.2. Synthesis of 6-bromo-2-[2-(2,6-
dichlorophenyl)amino]benzyl-4H-3,1-benzoxazin-4-one (2)
A mixture of 2-[(2,6-dichlorophenyl)amino]phenyl acetyl chlo-
ride 1 (0.02 mol) and 5-bromo anthranilic acid (0.02 mol) in
pyridine (40 ml) was stirred at 0–5 C for 1 h, further stirred
for 1 h at room temperature. A pasty mass obtained which
was washed thoroughly with sodium bicarbonate (5%) to re-
move unreacted acid. A solid separated was ﬁltered, dried
and recrystallized from methanol.
Yield 55%, m.p. 194–198 C. IR (KBr): t= 3446 (NH),
2926, 2850 (CH2), 1740 (C‚O), 1618 (C‚N), 1153 (C–O),
743 (C–Cl), 565 (C–Br) cm1. 1H NMR (400 MHz, CDCl3,
25 C, TMS): d= 3.53 (s, 2H, CH2), 6.38–8.16 (m, 10H,Ar–H), 9.10 (bs, 1H, NH) ppm; 13C NMR (100 MHz, CDCl3,
25 C, TMS) d= 32.43 (CH2), 116.31, 118.64, 120.62, 121.67,
124.31, 124.57, 126.54, 127.17, 127.43, 129.41, 131.12, 135.22,
137.29, 138.23, 141.78, 148.73 (Ar–C), 159.23 (C‚O), 164.33
(C‚N) ppm. Anal. For C21H13BrCl2N2O2 (476.15) calcd.
C52.97, H2.75, N5.88. Found C52.94, H2.71, N5.92.
2.3. Synthesis of 3-amino-6-bromo-2-[2-(2,6-
dichlorophenyl)amino]benzyl-quinazolin-4(3H)-one (3)
A mixture of 2 (0.01 mol) and hydrazine hydrate (0.02 mol) in
absolute methanol (20 ml) was reﬂuxed on water bath for 4–
6 h, excess of solvent was distilled off and the residue was
cooled whereupon a crystalline solid was separated out, which
was recrystallized from methanol.
Yield 58%, m.p. 178–182 C. IR (KBr): t= 3495–3405
(NH and NH2), 2922, 2848 (CH2), 1684 (C‚O), 1610
(C‚N), 755 (C–Cl), 570 (C–Br). 1H NMR (400 MHz, CDCl3,
25 C, TMS): d= 3.56 (s, 2H, CH2), 5.75 (bs, 2H, NH2), 6.39–
8.15 (m, 10H, Ar–H), 9.15 (bs, 1H, NH) ppm; 13C NMR
(100 MHz, CDCl3, 25 C, TMS) d= 30.57 (CH2), 116.14,
120.45, 121.52, 123.14, 124.23, 124.55, 126.74, 127.28, 127.49,
129.36, 131.13, 132.22, 136.45, 137.26, 141.78, 146.22 (Ar–C),
161.28 (C‚O), 164.53 (C‚N) ppm. Anal. For
C21H15BrCl2N4O (490.18) calcd. C51.46, H3.08, N11.43.
Found C51.38, H3.02, N11.39.2.4. General procedure for the synthesis of Schiff bases (4a–k)
To a mixture of 3 (0.005 mol) and substituted aromatic alde-
hydes (0.005 mol) in absolute ethanol (40 ml) was added few
drops of glacial acetic acid. Then the mixture was reﬂuxed
on water bath for 5–6 h. The excess of solvent was distilled
off, poured onto ice cold water. The separated solid was ﬁl-
tered, washed and recrystallized from ethanol.
2.4.1. 6-Bromo-2-[2-(2,6-dichlorophenyl)amino]benzyl-3-(2-
nitrobenzylideneamino)-quinazolin-4(3H)-one (4a)
Yield 58%, m.p. 163–167 C. IR (KBr): t= 3432 (NH), 2918,
2843 (CH2), 1675 (C‚O, quinazolinone), 1634 (N‚CH), 1612
(C‚N), 1550, 1362 (NO2), 755 (C–Cl), 585 (C–Br) cm
1. 1H
NMR (400 MHz, CDCl3, 25 C, TMS): d= 3.54 (s, 2H,
CH2), 6.23 (s, 1H, N‚CH), 6.37–8.15 (m, 14H, Ar–H), 9.15
(bs, 1H, NH) ppm; 13C NMR (100 MHz, CDCl3, 25 C,
TMS) d= 33.42 (CH2), 116.19, 120.47, 121.45, 123.11,
123.82, 124.30, 124.68, 126.73, 127.26, 127.41, 128.54, 129.35,
130.26, 131.17, 131.93, 132.12, 135.47, 136.42, 137.25, 141.83,
146.34, 148.67 (Ar–C), 144.25 (N‚CH), 159.22 (C‚O),
164.46 (C‚N) ppm. Anal. For C28H18BrCl2N5O3 (623.28)
calcd. C53.96, H2.91, N11.24. Found C53.88, H2.86, N11.17.
2.4.2. 6-Bromo-2-[2-(2,6-dichlorophenyl)amino]benzyl-3-(3-
nitrobenzylideneamino)-quinazolin-4(3H)-one (4b)
Yield 53%, m.p. 150–156 C. IR (KBr): t= 3435 (NH), 2920,
2850 (CH2), 1677 (C‚O, quinazolinone), 1635 (N‚CH), 1615
(C‚N), 1553, 1365 (NO2), 744 (C–Cl), 578 (C–Br) cm
1. 1H
NMR (400 MHz, CDCl3, 25 C, TMS): d= 3.55 (s, 2H,
CH2), 6.25 (s, 1H, N‚CH), 6.38–8.39 (m, 14H, Ar–H), 9.14
(bs, 1H, NH) ppm; 13C NMR (100 MHz, CDCl3, 25 C,
TMS) d= 33.52 (CH2), 116.07, 120.54, 121.56, 122.64,
123.23, 124.32, 124.48, 125.87, 126.81, 127.27, 127.36, 129.44,
Synthesis and antimicrobial activity of Schiff bases and 2-azetidinones derived from quinazolin-4(3H)-one 405129.53, 131.18, 132.29, 133.92, 134.83, 136.44, 137.17, 141.76,
146.24, 149.16 (Ar–C), 144.16 (N‚CH), 159.43 (C‚O),
164.34 (C‚N) ppm. Anal. For C28H18BrCl2N5O3 (623.28)
calcd. C53.96, H2.91, N11.24. Found C53.85, H2.95, N11.19.
2.4.3. 6-Bromo-2-[2-(2,6-dichlorophenyl)amino]benzyl-3-(2-
hydroxybenzylideneamino)-quinazolin-4(3H)-one (4c)
Yield 52%, m.p. 155–159 C. IR (KBr): t= 3445 (NH), 3255
(OH), 2925, 2852 (CH2), 1685 (C‚O, quinazolinone), 1628
(N‚CH), 1612 (C‚N), 745 (C–Cl), 575 (C–Br) cm1. 1H
NMR (400 MHz, CDCl3, 25 C, TMS): d= 3.60 (s, 2H,
CH2), 5.65 (bs, 1H, OH), 6.22 (s, 1H, N‚CH), 6.37–8.16
(m, 14H, Ar–H), 9.13 (bs, 1H, NH) ppm; 13C NMR
(100 MHz, CDCl3, 25 C, TMS) d= 33.67 (CH2), 114.53,
116.22, 117.89, 120.55, 121.25, 121.53, 123.17, 124.33, 124.52,
126.72, 127.22, 127.55, 129.51, 130.43, 131.21, 132.23, 133.12,
136.45, 137.15, 141.72, 146.26, 158.84 (Ar–C), 143.92
(N‚CH), 159.38 (C‚O), 164.25 (C‚N) ppm. Anal. For
C28H19BrCl2N4O2 (594.29) calcd. C56.59, H3.22, N9.43.
Found C56.48, H3.16, N9.51.
2.4.4. 6-Bromo-2-[2-(2,6-dichlorophenyl)amino]benzyl-3-(4-
hydroxybenzylideneamino)-quinazolin-4(3H)-one (4d)
Yield 54%, m.p. 163–168 C. IR (KBr): t= 3440 (NH), 3250
(OH), 2923, 2842 (CH2), 1680 (C‚O, quinazolinone), 1635
(N‚CH), 1608 (C‚N), 749 (C–Cl), 582 (C–Br) cm1. 1H
NMR (400 MHz, CDCl3, 25 C, TMS): d= 3.58 (s, 2H,
CH2), 5.60 (bs, 1H, OH), 6.20 (s, 1H, N‚CH), 6.38–8.14 (m,
14H, Ar–H), 9.20 (bs, 1H, NH) ppm; 13C NMR (100 MHz,
CDCl3, 25 C, TMS) d= 33.47 (CH2), 114.23, 116.32,
120.66, 121.65, 123.05, 124.34, 124.56, 125.67, 126.73, 127.29,
127.58, 129.45, 130.36, 131.21, 132.12, 136.49, 137.27, 141.68,
146.19, 158.63 (Ar–C), 143.87 (N‚CH), 159.26 (C‚O),
164.46 (C‚N) ppm. Anal. For C28H19BrCl2N4O2 (594.29)
calcd. C56.59, H3.22, N9.43. Found C56.51, H3.17, N9.38.2.4.5. 6-Bromo-3-(2-chlorobenzylideneamino)-2-[2-(2,6-
dichlorophenyl)amino]benzyl-quinazolin-4(3H)-one (4e)
Yield 58%, m.p. 140–146 C. IR (KBr): t= 3449 (NH), 2916,
2845 (CH2), 1674 (C‚O, quinazolinone), 1631 (N‚CH), 1614
(C‚N), 743 (C–Cl), 570 (C–Br) cm1. 1H NMR (400 MHz,
CDCl3, 25 C, TMS): d= 3.55 (s, 2H, CH2), 6.21 (s, 1H,
N‚CH), 6.37–8.15 (m, 14H, Ar–H), 9.17 (bs, 1H, NH)
ppm; 13C NMR (100 MHz, CDCl3, 25 C, TMS) d= 33.23
(CH2), 116.12, 120.47, 121.63, 123.10, 124.27, 124.44, 126.72,
126.93, 127.23, 127.43, 128.23, 129.42, 130.52, 131.15, 132.17,
132.86, 134.48, 135.12, 136.54, 137.26, 141.73, 146.12 (Ar–C),
144.08 (N‚CH), 159.46 (C‚O), 164.35 (C‚N) ppm. Anal.
For C28H18BrCl3N4O (612.73) calcd. C54.89, H2.96, N9.14.
Found C54.78, H2.87, N9.10.2.4.6. 6-Bromo-3-(4-chlorobenzylideneamino)-2-[2-(2,6-
dichlorophenyl)amino]benzyl-quinazolin-4(3H)-one (4f)
Yield 55%, m.p. 154–161 C. IR (KBr): t= 3448 (NH), 2926,
2855 (CH2), 1678 (C‚O, quinazolinone), 1635 (N‚CH),
1617 (C‚N), 754 (C–Cl), 575 (C–Br) cm1. 1H NMR
(400 MHz, CDCl3, 25 C, TMS): d= 3.52 (s, 2H, CH2), 6.23
(s, 1H, N‚CH), 6.40–8.16 (m, 14H, Ar–H), 9.14 (bs, 1H, NH)
ppm; 13C NMR (100 MHz, CDCl3, 25 C, TMS) d= 33.32
(CH2), 116.10, 120.55, 121.56, 123.19, 124.23, 124.58, 126.83,
127.22, 127.46, 128.62, 129.47, 130.24, 131.14, 132.26,133.35, 136.42, 136.86, 137.28, 141.85, 146.28 (Ar–C), 144.12
(N‚CH), 159.36 (C‚O), 164.48 (C‚N) ppm. Anal. For




Yield 56%, m.p. 160–166 C. IR (KBr): t= 3435 (NH), 2924,
2850 (CH2), 1672 (C‚O, quinazolinone), 1637 (N‚CH), 1607
(C‚N), 1204, 1106 (C–O–C), 757 (C–Cl), 582 (C–Br) cm1.
1H NMR (400 MHz, CDCl3, 25 C, TMS): d= 3.58 (s, 2H,
CH2), 3.62 (s, 3H, OCH3), 6.19 (s, 1H, N‚CH), 6.37–8.14
(m, 14H, Ar–H), 9.16 (bs, 1H, NH) ppm; 13C NMR
(100 MHz, CDCl3, 25 C, TMS) d= 33.52 (CH2), 53.68
(OCH3), 113.38, 116.05, 120.50, 121.46, 123.14, 124.35,
124.66, 125.73, 126.79, 127.18, 127.36, 129.35, 130.46, 131.15,
132.17, 136.45, 137.20, 141.79, 146.38, 161.37 (Ar–C), 144.37
(N‚CH), 159.25 (C‚O), 164.31 (C‚N) ppm. Anal. For
C29H21BrCl2N4O2 (608.31) calcd. C57.26, H3.48, N9.21.




Yield 54%, m.p. 162–168 C. IR (KBr): t= 3440 (NH), 2926,
2852 (CH2), 1675 (C‚O, quinazolinone), 1633 (N‚CH), 1610
(C‚N), 1203, 1102 (C–O–C), 741 (C–Cl), 567 (C–Br) cm1.
1H NMR (400 MHz, CDCl3, 25 C, TMS): d= 3.55 (s, 2H,
CH2), 3.65 (s, 9H, (OCH3)3), 6.25 (s, 1H, N‚CH), 6.36–8.15
(m, 12H, Ar–H), 9.14 (bs, 1H, NH) ppm; 13C NMR
(100 MHz, CDCl3, 25 C, TMS) d= 33.59 (CH2), 55.76
(OCH3), 55.38 (OCH3), 110.15, 116.23, 120.54, 121.53,
123.22, 124.35, 124.45, 126.87, 127.24, 127.56, 128.32, 129.43,
131.20, 132.26, 136.52, 137.17, 141.75, 142.17, 146.17, 149.46
(Ar–C), 144.29 (N‚CH), 159.63 (C‚O), 164.43 (C‚N)
ppm. Anal. For C31H25BrCl2N4O4 (668.36) calcd. C55.71,




Yield 56%, m.p. 150–155 C. IR (KBr): t= 3443 (NH), 3252
(OH), 2923, 2853 (CH2), 1682 (C‚O, quinazolinone), 1637
(N‚CH), 1612 (C‚N), 1207, 1100 (C–O–C), 753 (C–Cl), 580
(C–Br) cm1. 1H NMR (400 MHz, CDCl3, 25 C, TMS):
d= 3.56 (s, 2H, CH2), 3.65 (s, 3H, OCH3), 5.62 (bs, 1H, OH),
6.18 (s, 1H, N‚CH), 6.39–8.13 (m, 13H, Ar–H), 9.18 (bs, 1H,
NH) ppm; 13C NMR (100 MHz, CDCl3, 25 C, TMS)
d= 33.54 (CH2), 52.43 (OCH3), 98.68, 105.13, 107.86, 116.16,
120.55, 121.56, 123.12, 124.34, 124.52, 126.82, 127.22, 127.44,
129.47, 131.19, 131.83, 132.24, 136.46, 137.23, 141.82, 146.31,
157.77, 161.26 (Ar–C), 144.18 (N‚CH), 159.16 (C‚O),
164.56 (C‚N) ppm. Anal. For C29H21BrCl2N4O3




Yield 50%, m.p. 158–163 C. IR (KBr): t= 3448 (NH), 2922,
2849 (CH2), 1678 (C‚O, quinazolinone), 1635 (N‚CH), 1613
(C‚N), 744 (C–Cl), 568 (C–Br) cm1. 1H NMR (400 MHz,
CDCl3, 25 C, TMS): d= 2.84 (s, 6H, N(CH3)2), 3.57 (s,
406 N.B. Patel, J.C. Patel2H, CH2), 6.25 (s, 1H, N‚CH), 6.37–8.12 (m, 14H, Ar–H),
9.14 (bs, 1H, NH) ppm; 13C NMR (100 MHz, CDCl3, 25 C,
TMS) d= 33.72 (CH2), 42.58 (N(CH3)2), 111.83, 116.25,
120.45, 121.56, 123.05, 123.76, 124.33, 124.42, 126.90, 127.16,
127.56, 129.37, 130.32, 131.24, 132.19, 136.53, 137.18, 141.95,
146.27, 149.34 (Ar–C), 143.95 (N‚CH), 159.64 (C‚O),
164.37 (C‚N) ppm. Anal. For C30H24BrCl2N5O (621.35)




Yield 60%, m.p. 156–162 C. IR (KBr): t= 3445 (NH), 3260
(OH), 2922, 2850 (CH2), 1679 (C‚O, quinazolinone), 1636
(N‚CH), 1605 (C‚N), 758 (C–Cl), 592 (C–Br) cm1. 1H
NMR (400 MHz, CDCl3, 25 C, TMS): d= 1.34 (t, 6H,
N(CH2CH3)2, J= 7.6 Hz), 2.82 (q, 4H, N(CH2CH3)2,
J= 7.6 Hz), 3.56 (s, 2H, CH2), 5.66 (s, 1H, OH), 6.22 (s,
1H, N‚CH), 6.38–8.16 (m, 13H, Ar–H), 9.18 (bs, 1H, NH)
ppm; 13C NMR (100 MHz, CDCl3, 25 C, TMS) d= 14.56
(N(CH2CH3)2), 33.42 (CH2), 43.74 (N(CH2CH3)2), 97.16,
105.12, 105.43, 116.29, 120.47, 121.57, 123.13, 124.34, 124.46,
126.92, 127.16, 127.53, 129.37, 131.23, 131.67, 132.19, 136.55,
137.20, 141.93, 146.11, 150.27, 158.46 (Ar–C), 144.05
(N‚CH), 159.55 (C‚O), 164.46 (C‚N) ppm. Anal. For
C32H28BrCl2N5O2 (665.41) calcd. C57.76, H4.24, N10.52.
Found C57.68, H4.18, N10.56.
2.5. General procedure for the synthesis of 2-azetidinones (5a–k)
A solution of 4a–k (0.0025 mol) in dry dioxane (20 ml) was
added to a well stirred mixture of chloro acetyl chloride
(0.0025 mol) and triethylamine (0.0025 mol) in dry dioxane
(20 ml) at 0–5 C. The reaction mixture was stirred for 10–
12 h and kept for two days at room temperature. The product




Yield 54%, m.p. 178–183 C. IR (KBr): t= 3425 (NH), 2919,
2845 (CH2), 1751 (C‚O, azetidinone), 1675 (C‚O, quinazoli-
none), 1613 (C‚N), 1556, 1365 (NO2), 754 (C–Cl), 570 (C–Br)
cm1. 1H NMR (400 MHz, CDCl3, 25 C, TMS): d= 3.28 (d,
1H, N–CH, J= 5.2 Hz), 3.35 (d, 1H, CH–Cl, J= 5.2 Hz),
3.55 (s, 2H, CH2), 6.38–8.15 (m, 14H, Ar–H), 9.15 (bs, 1H,
NH) ppm; 13C NMR (100 MHz, CDCl3, 25 C, TMS)
d= 31.46 (CH2), 54.28 (N–CH), 65.44 (CH–Cl), 116.21,
120.46, 121.37, 123.16, 123.52, 124.23, 124.72, 126.78, 127.31,
127.43, 128.12, 128.54, 129.32, 131.25, 132.18, 135.37, 136.45,
136.78, 137.16, 141.88, 146.32, 148.43 (Ar–C), 161.46 (C‚O,
quinazolinone), 161.88 (C‚O, azetidinone), 164.32 (C‚N)
ppm. Anal. For C30H19BrCl3N5O4 (699.77) calcd. C51.49,




Yield 56%, m.p. 155–161 C. IR (KBr): t= 3418 (NH), 2917,
2842 (CH2), 1748 (C‚O, azetidinone), 1673 (C‚O, quinazoli-
none), 1612 (C‚N), 1558, 1364 (NO2), 742 (C–Cl), 579 (C–Br)
cm1. 1H NMR (400 MHz, CDCl3, 25 C, TMS): d= 3.23 (d,1H, N–CH, J= 5.3 Hz), 3.34 (d, 1H, CH–Cl, J= 5.3 Hz),
3.53 (s, 2H, CH2), 6.38–8.40 (m, 14H, Ar–H), 9.16 (bs, 1H,
NH) ppm; 13C NMR (100 MHz, CDCl3, 25 C, TMS)
d= 31.57 (CH2), 57.32 (N–CH), 62.68 (CH–Cl), 116.15,
119.86, 120.53, 121.46, 122.87, 123.34, 124.23, 124.53, 126.84,
127.28, 127.47, 129.43, 130.05, 131.16, 132.24, 134.72, 136.47,
137.22, 141.85, 142.46, 146.29, 148.18 (Ar–C), 161.37 (C‚O,
quinazolinone), 161.96 (C‚O, azetidinone), 164.65 (C‚N)
ppm. Anal. For C30H19BrCl3N5O4 (699.77) calcd. C51.49,




Yield 51%, m.p. 160–166 C. IR (KBr): t= 3440 (NH), 3260
(OH), 2920, 2845 (CH2), 1750 (C‚O, azetidinone), 1675
(C‚O, quinazolinone), 1610 (C‚N), 745 (C–Cl), 573 (C–
Br) cm1. 1H NMR (400 MHz, CDCl3, 25 C, TMS):
d= 3.30 (d, 1H, N–CH, J= 5.2 Hz), 3.38 (d, 1H, CH–Cl,
J= 5.2 Hz), 3.59 (s, 2H, CH2), 5.64 (bs, 1H, OH), 6.38–8.15
(m, 14H, Ar–H), 9.14 (bs, 1H, NH) ppm; 13C NMR
(100 MHz, CDCl3, 25 C, TMS) d= 31.63 (CH2), 55.65 (N–
CH), 63.48 (CH–Cl), 113.17, 116.19, 120.46, 120.78, 121.64,
123.28, 124.23, 124.42, 126.78, 127.22, 127.47, 128.36, 128.84,
129.49, 129.76, 131.13, 132.35, 136.57, 137.25, 141.83, 146.32,
156.42 (Ar–C), 161.34 (C‚O, quinazolinone), 161.56 (C‚O,
azetidinone), 164.53 (C‚N) ppm. Anal. For C30H20BrCl3N4O3





Yield 62%, m.p. 165–170 C. IR (KBr): t= 3443 (NH), 3255
(OH), 2923, 2852 (CH2), 1751 (C‚O, azetidinone), 1677
(C‚O, quinazolinone), 1613 (C‚N), 757 (C–Cl), 566 (C–
Br) cm1. 1H NMR (400 MHz, CDCl3, 25 C, TMS):
d= 3.29 (d, 1H, N–CH, J= 5.5 Hz), 3.40 (d, 1H, CH–Cl,
J= 5.5 Hz), 3.59 (s, 2H, CH2), 5.62 (bs, 1H, OH), 6.37–8.15
(m, 14H, Ar–H), 9.18 (bs, 1H, NH) ppm; 13C NMR
(100 MHz, CDCl3, 25 C, TMS) d= 31.52 (CH2), 58.78 (N–
CH), 66.73 (CH–Cl), 114.52, 116.23, 120.46, 121.56, 123.12,
124.32, 124.68, 126.83, 127.33, 127.50, 129.52, 130.18, 131.13,
132.26, 134.89, 136.42, 137.26, 141.95, 146.23, 157.93
(Ar–C), 161.52 (C‚O, quinazolinone), 161.78 (C‚O, azetidi-
none), 164.29 (C‚N) ppm. Anal. For C30H20BrCl3N4O3





Yield 58%, m.p. 167–173 C. IR (KBr): t= 3449 (NH), 2918,
2846 (CH2), 1745 (C‚O, azetidinone), 1675 (C‚O, quinazoli-
none), 1614 (C‚N), 744 (C–Cl), 580 (C–Br) cm1. 1H NMR
(400 MHz, CDCl3, 25 C, TMS): d= 3.25 (d, 1H, N–CH,
J= 5.3 Hz), 3.37 (d, 1H, CH–Cl, J= 5.3 Hz), 3.58 (s, 2H,
CH2), 6.36–8.16 (m, 14H, Ar–H), 9.16 (bs, 1H, NH) ppm;
13C NMR (100 MHz, CDCl3, 25 C, TMS) d= 31.74 (CH2),
56.62 (N–CH), 65.54 (CH–Cl), 116.21, 120.54, 121.55,
123.19, 124.23, 124.38, 125.53, 126.82, 127.29, 127.44, 127.85,









































































Synthesis and antimicrobial activity of Schiff bases and 2-azetidinones derived from quinazolin-4(3H)-one 407141.76, 142.38, 146.06 (Ar–C), 161.35 (C‚O, quinazolinone),
161.73 (C‚O, azetidinone), 164.34 (C‚N) ppm. Anal. For
C30H19BrCl4N4O2 (689.21) calcd. C52.28, H2.78, N8.13.




Yield 65%, m.p. 173–180 C. IR (KBr): t= 3450 (NH), 2921,
2853 (CH2), 1747 (C‚O, azetidinone), 1684 (C‚O, quinazoli-
none), 1617 (C‚N), 760 (C–Cl), 585 (C–Br) cm1. 1H NMR
(400 MHz, CDCl3, 25 C, TMS): d= 3.24 (d, 1H, N–CH,
J= 5.5 Hz), 3.35 (d, 1H, CH–Cl, J= 5.5 Hz), 3.53 (s, 2H,
CH2), 6.41–8.15 (m, 14H, Ar–H), 9.13 (bs, 1H, NH) ppm;
13C NMR (100 MHz, CDCl3, 25 C, TMS) d= 31.37 (CH2),
58.66 (N–CH), 63.62 (CH–Cl), 116.15, 120.43, 121.43,
123.12, 124.35, 124.53, 126.84, 127.23, 127.47, 128.17, 128.48,
129.44, 131.13, 132.36, 132.67, 136.52, 137.26, 141.81, 142.23,146.15 (Ar–C), 161.26 (C‚O, quinazolinone), 162.04 (C‚O,
azetidinone), 164.51 (C‚N) ppm. Anal. For C30H19BrCl4





Yield 62%, m.p. 152–156 C. IR (KBr): t= 3422 (NH), 2930,
2855 (CH2), 1748 (C‚O, azetidinone), 1672 (C‚O, quinazoli-
none), 1612 (C‚N), 1212, 1108 (C–O–C), 755 (C–Cl), 595 (C–
Br) cm1. 1H NMR (400 MHz, CDCl3, 25 C, TMS): d= 3.25
(d, 1H, N–CH, J= 5.3 Hz), 3.36 (d, 1H, CH–Cl, J= 5.3 Hz),
3.56 (s, 2H, CH2), 3.63 (s, 3H, OCH3), 6.38–8.14 (m, 14H, Ar–
H), 9.15 (bs, 1H, NH) ppm; 13C NMR (100 MHz, CDCl3,
25 C, TMS) d= 31.26 (CH2), 53.76 (OCH3), 58.57 (N–CH),
64.43 (CH–Cl), 113.32, 116.18, 120.41, 121.37, 123.26,
124.28, 124.55, 126.79, 127.25, 127.48, 128.23, 129.42, 131.16,
Table 1 Gram positive antibacterial activity of compounds 4a–k and 5a–k.
Compound R S. aureus ATCC 9144 Potency (%) B. subtilis ATCC 6633 Potency (%)
Std.: penicillin-G Std.: penicillin-G
UH UL SH SL UH UL SH SL
4a 2-NO2 3 2 12 8 29.60 4 3 15 9 28.92
4b 3-NO2 2 1 12 7 23.76 2 2 15 9 18.22
4c 2-OH 4 2 12 8 38.83 4 3 15 9 28.92
4d 4-OH 3 3 12 8 24.19 3 2 15 9 24.99
4e 2-Cl 6 3 12 8 52.88 5 3 15 9 36.00
4f 4-Cl 6 4 12 8 50.88 8 5 15 9 53.56
4g 4-OCH3 6 4 12 8 50.88 9 5 15 9 60.00
4h 3,4,5-(OCH3)3 6 5 12 8 48.20 8 5 15 9 53.56
4i 2-OH-4-OCH3 6 5 12 8 48.20 6 4 16 9 38.33
4j 4-N(CH3)2 0 0 12 8 0 0 0 15 9 0
4k 2-OH-4-N(C2H5)2 0 0 12 8 0 0 0 15 9 0
5a 2-NO2 3 2 12 8 29.63 5 4 15 9 33.47
5b 3-NO2 4 0 12 8 44.44 3 3 15 9 21.60
5c 2-OH 4 2 12 8 38.83 3 3 15 9 21.60
5d 4-OH 5 2 12 8 47.09 6 3 15 9 42.68
5e 2-Cl 4 2 13 8 35.33 4 3 15 9 28.92
5f 4-Cl 6 5 12 8 48.20 8 5 15 9 53.56
5g 4-OCH3 6 4 12 8 50.88 9 5 15 9 60.00
5h 3,4,5-(OCH3)3 6 4 12 8 50.88 7 4 15 9 47.81
5i 2-OH-4-OCH3 4 3 12 8 34.85 6 4 15 9 40.90
5j 4-N(CH3)2 0 0 12 7 0 1 0 15 8 0
5k 2-OH-4-N(C2H5)2 0 0 12 8 0 0 0 15 9 0
UH: zone of inhibition of compound at 100 lg/ml; UL: zone of inhibition of compound at 50 lg/ml; SH: zone of inhibition of standard at 100 lg/
ml; SL: zone of inhibition of standard at 50 lg/ml.
Table 2 Gram negative antibacterial activity of compounds 4a–k and 5a–k.
Compound R P. aeruginosa ATCC 9027 Potency (%) E. coli ATCC 25922 Potency (%)
Std.: penicillin-G Std.: penicillin-G
UH UL SH SL UH UL SH SL
4a 2-NO2 3 2 13 8 27.40 3 2 14 9 26.57
4b 3-NO2 2 1 12 8 25.19 3 2 14 9 26.57
4c 2-OH 3 2 12 8 29.63 4 4 14 9 26.57
4d 4-OH 4 2 12 7 36.75 3 3 14 8 22.49
4e 2-Cl 5 3 12 8 44.44 5 3 14 9 38.80
4f 4-Cl 7 5 12 8 58.24 6 5 14 9 41.33
4g 4-OCH3 7 5 12 8 58.24 8 6 14 9 56.66
4h 3,4,5-(OCH3)3 7 5 12 8 58.24 7 5 14 9 49.94
4i 2-OH-4-OCH3 4 3 12 8 34.85 5 3 14 9 38.80
4j 4-N(CH3)2 0 0 12 7 0 0 0 14 9 0
4k 2-OH-4-N(C2H5)2 0 0 12 8 0 0 0 15 9 0
5a 2-NO2 5 2 12 8 47.09 4 3 14 9 30.78
5b 3-NO2 4 3 12 7 34.03 4 3 14 9 30.78
5c 2-OH 5 3 12 8 44.44 4 2 14 9 34.20
5d 4-OH 6 3 12 8 52.88 5 3 14 9 38.80
5e 2-Cl 3 2 12 8 29.63 4 2 14 9 34.20
5f 4-Cl 7 5 12 8 58.24 7 5 14 9 49.94
5g 4-OCH3 8 5 13 8 61.54 9 5 14 9 64.29
5h 3,4,5-(OCH3)3 7 5 12 8 58.24 7 4 15 8 47.03
5i 2-OH-4-OCH3 4 3 12 8 34.85 6 4 14 9 44.02
5j 4-N(CH3)2 0 0 12 8 0 1 0 14 9 0
5k 2-OH-4-N(C2H5)2 0 0 12 8 0 0 0 14 9 0
UH: zone of inhibition of compound at 100 lg/ml; UL: zone of inhibition of compound at 50 lg/ml; SH: zone of inhibition of standard at 100 lg/
ml; SL: zone of inhibition of standard at 50 lg/ml.
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161.57 (C‚O, quinazolinone), 162.12 (C‚O, azetidinone),
164.56 (C‚N) ppm. Anal. For C31H22BrCl3N4O3 (684.79)




Yield 57%, m.p. 167–175 C. IR (KBr): t= 3420 (NH), 2925,
2840 (CH2), 1745 (C‚O, azetidinone), 1668 (C‚O, quinazoli-
none), 1610 (C‚N), 1210, 1105 (C–O–C), 750 (C–Cl), 565 (C–
Br) cm1. 1H NMR (400 MHz, CDCl3, 25 C, TMS): d= 3.24
(d, 1H, N–CH, J= 5.2 Hz), 3.34 (d, 1H, CH–Cl, J= 5.2 Hz),
3.54 (s, 2H, CH2), 3.64 (s, 9H, (OCH3)3), 6.37–8.16 (m, 12H,
Ar–H), 9.13 (bs, 1H, NH) ppm; 13C NMR (100 MHz, CDCl3,
25 C, TMS) d= 31.42 (CH2), 55.67 (OCH3), 55.24 (OCH3),
61.73 (N–CH), 64.36 (CH–Cl), 108.36, 116.14, 120.51,
121.66, 123.35, 124.32, 124.51, 126.73, 127.28, 127.44, 129.36,
131.11, 132.19, 136.58, 137.23, 139.18, 140.16, 141.83, 146.24,
149.73 (Ar–C), 161.64 (C‚O, quinazolinone), 162.06 (C‚O,
azetidinone), 164.47 (C‚N) ppm. Anal. For C33H26BrCl3





Yield 53%, m.p. 168–174 C. IR (KBr): t= 3428 (NH), 3257
(OH), 2927, 2853 (CH2), 1752 (C‚O, azetidinone), 1679
(C‚O, quinazolinone), 1614 (C‚N), 1208, 1104 (C–O–C),Table 3 Antifungal activity of compounds 4a–k and 5a–k.

























UH: zone of inhibition of compound at 100 lg/ml; UL: zone of inhibition o
ml; SL: zone of inhibition of standard at 50 lg/ml.749 (C–Cl), 573 (C–Br) cm1. 1H NMR (400 MHz, CDCl3,
25 C, TMS): d= 3.27 (d, 1H, N–CH, J= 5.5 Hz), 3.36 (d,
1H, CH–Cl, J= 5.5 Hz), 3.55 (s, 2H, CH2), 3.63 (s, 3H,
OCH3), 5.61 (bs, 1H, OH), 6.39–8.14 (m, 13H, Ar–H), 9.17
(bs, 1H, NH) ppm; 13C NMR (100 MHz, CDCl3, 25 C,
TMS) d= 31.35 (CH2), 52.56 (OCH3), 54.82 (N–CH), 64.63
(CH–Cl), 97.86, 104.97, 116.12, 120.54, 121.43, 122.86,
123.18, 124.32, 124.46, 126.84, 127.31, 127.37, 128.53, 129.44,
131.19, 132.34, 136.58, 137.22, 141.76, 146.47, 156.34, 158.78
(Ar–C), 161.55 (C‚O, quinazolinone), 161.98 (C‚O, azetidi-
none), 164.59 (C‚N) ppm. Anal. For C31H22BrCl3N4O4




Yield 51%, m.p. 173–176 C. IR (KBr): t= 3448 (NH), 2922,
2852 (CH2), 1745 (C‚O, azetidinone), 1682 (C‚O, quinazoli-
none), 1615 (C‚N), 751 (C–Cl), 576 (C–Br) cm1. 1H NMR
(400 MHz, CDCl3, 25 C, TMS): d= 2.85 (s, 6H, N(CH3)2),
3.28 (d, 1H, N–CH, J= 5.4 Hz), 3.39 (d, 1H, CH–Cl,
J= 5.4 Hz), 3.56 (s, 2H, CH2), 6.37–8.13 (m, 14H,
Ar–H), 9.16 (bs, 1H, NH) ppm; 13C NMR (100 MHz, CDCl3,
25 C, TMS) d= 31.46 (CH2), 42.78 (N(CH3)2), 57.37 (N–
CH), 62.48 (CH–Cl), 112.87, 116.23, 120.53, 121.64, 123.12,
124.34, 124.55, 126.73, 127.21, 127.47, 128.19, 129.52, 131.21,
132.24, 135.37, 136.63, 137.19, 141.68, 146.21, 148.29 (Ar–C),
161.76 (C‚O, quinazolinone), 162.32 (C‚O, azetidinone),CC 10231 Potency (%)
ricine-B
UL SH SL
1 9 4 25.88
1 9 4 25.88
0 9 4 0
0 9 4 19.75
1 9 4 25.88
2 9 4 44.44
2 9 4 44.44
1 9 4 35.25
0 9 4 0
0 9 4 19.75
0 9 4 19.75
1 9 4 35.25
1 9 4 25.88
0 9 4 0
1 9 4 25.88
1 9 4 35.25
3 9 4 56.03
2 9 4 44.44
1 9 4 35.25
0 9 4 19.75
0 9 4 19.75
0 9 4 19.75
f compound at 50 lg/ml; SH: zone of inhibition of standard at 100 lg/
410 N.B. Patel, J.C. Patel164.47 (C‚N) ppm. Anal. For C32H25BrCl3N5O2 (697.84)




Yield 64%, m.p. 178–185 C. IR (KBr): t= 3446 (NH), 3265
(OH), 2923, 2852 (CH2), 1750 (C‚O, azetidinone), 1680
(C‚O, quinazolinone), 1606 (C‚N), 760 (C–Cl), 582 (C–Br)
cm1. 1H NMR (400 MHz, CDCl3, 25 C, TMS): d= 1.33 (t,
6H, N(CH2CH3)2, J= 7.6 Hz), 2.84 (q, 4H, N(CH2CH3)2,
J= 7.6 Hz), 3.30 (d, 1H, N–CH, J= 5.5 Hz), 3.38 (d, 1H,
CH–Cl, J= 5.5 Hz), 3.55 (s, 2H, CH2), 5.65 (s, 1H, OH),
6.39–8.15 (m, 13H, Ar–H), 9.17 (bs, 1H, NH) ppm; 13C NMR
(100 MHz, CDCl3, 25 C, TMS) d= 14.73 (N(CH2CH3)2),
31.53 (CH2), 43.83 (N(CH2CH3)2), 56.76 (N–CH), 65.28 (CH–
Cl), 95.76, 104.34, 116.27, 118.76, 120.63, 121.50, 123.08,
124.26, 124.42, 126.62, 127.33, 127.55, 128.63, 129.44, 131.27,
132.23, 136.48, 137.29, 141.77, 146.16, 148.87, 156.45
(Ar–C), 161.67 (C‚O, quinazolinone), 162.23 (C‚O, azetidi-
none), 164.63 (C‚N) ppm. Anal. For C34H29BrCl3N5O3
(741.89) calcd. C55.04, H3.94, N9.44. Found C54.95, H3.98,
N9.39.
2.6. Antimicrobial activity
The in vitro antimicrobial activity of compounds 4a–k and 5a–k
were carried out by cup-plate method (Barry, 1976). Antibacte-
rial activity was screened against two gram positive bacteria
(Staphylococcus aureus ATCC 9144 and Bacillus subtilis ATCC
6633) and two gram negative bacteria (Pseudomonas aeruginosa
ATCC 9027 andE. coli ATCC 25922), while antifungal activity
was screened against fungi Candida albicans ATCC 10231 by
measuring the zone of inhibition on agar plates at two different
concentrations 100 and 50 lg/ml. Penicillin-G was used as a
standard antibacterial agent whereas amphotericine-B was
used as a standard antifungal agent. Microbial cultures were
obtained from National Collection of Industrial Microorgan-
isms (NCIM), National Chemical Laboratory, Pune. The po-
tency of the compounds was calculated by using the
following formula as per Edwin and Marion (1945).
Potency ¼ fantilog½ðD=BÞ  Ig M F
where F= dilution factor = 1 (same dilution used for stan-
dard and test); M= potency of standard = 100; I= log SH/
SL; D= (UH + UL)  (SH + SL); B= (UH  UL) + (SH 
SL); UH = zone of inhibition of compound at 100 lg/ml;
UL = zone of inhibition of compound at 50 lg/ml; SH = zone
of inhibition of standard at 100 lg/ml; SL = zone of inhibition
of standard at 50 lg/ml.
3. Results and discussion
3.1. Chemistry
The title compounds, 6-bromo-2-[2-(2,6-dichlorophenyl)amino]-
benzyl-3-substituted benzylideneamino-quinazolin-4(3H)-ones
4a–k and 6-bromo-3-(3-chloro-4-substituted phenyl-2-oxoaz-
etidin-1-yl)-2-[2-(2,6-dichlorophenyl)amino]benzyl-quinazolin-
4(3H)-ones 5a–k, have been synthesized according to the
described process in Scheme 1. The structures of all the com-pounds were established on the basis of elemental analyses,
IR, 1H NMR, and 13C NMR spectral data. The required ben-
zoxazinone 2 was prepared by the cyclization reaction between
5-bromo anthranilic acid and 2-[(2,6-dichlorophenyl)-
amino]phenyl acetyl chloride 1 using pyridine. The formation
of the product was conﬁrmed by a sharp band at 1740 cm1
for C‚O group along with a band at 1153 cm1 for C–O
stretching in the IR spectrum. Compound 2 was converted
to quinazolin-4(3H)-one 3, by its condensation reaction with
hydrazine hydrate in methanol. The disappearance of the C–
O stretching band at 1153 cm1 and the presence of a sharp
C‚O stretching band at 1684 cm1 instead of a C‚O stretch-
ing band at 1740 cm1 conﬁrmed the formation of quinazoli-
4(3H)-one. This was further conﬁrmed by 13C NMR spectrum,
which showed C‚O and C‚N signals of quinazolinone at d
161.2 ppm and d 164.5 ppm, respectively. When compound 3
was treated with substituted aromatic aldehydes in the pres-
ence of glacial acetic acid as a catalyst, Schiff bases 4a–k were
formed, which were conﬁrmed by the presence of strong
–N‚CH– stretching vibration of the Schiff bases at around
1630 cm1 and 1H NMR spectra showed a singlet at around
d 6.20 ppm due to one proton of the Schiff base. Further cycli-
zation reaction of Schiff bases 4a–k with chloro acetyl chloride
in the presence of triethylamine as a catalyst at 0–5 C gave the
desired compounds 2-oxo-azetidinyl-quinazolin-4(3H)-ones
5a–k. IR spectra of compounds 5a–k showed strong stretching
vibration at around 1750 cm1 due to C‚O group of 2-azetid-
inone. 1H NMR spectra of 5a–k showed a doublet at around d
3.26 ppm and d 3.37 ppm equivalent to one proton due to
N–CH and CH–Cl of 2-azetidinone ring, respectively.
3.2. Antimicrobial activity
The results of antibacterial activity are shown in Tables 1 and
2. Schiff base derivatives 4e, 4f, 4g and 2-azetidinone deriva-
tives 5g and 5h exhibited good activities (50.88–52.88%)
against gram positive bacteria S. aureus while compounds 4g
and 5g displayed good activity (60%) against gram positive
bacteria B. subtilis. Schiff bases as well as 2-azetidinones 4f,
4g, 4h, 5f, 5g and 5h showed good activities (58.24–61.54%)
against gram negative bacteria P. aeruginosa whereas com-
pounds 4g and 5g showed good activities (56.66% and
64.29%, respectively) against gram negative bacteria E. coli.
The remaining compounds possess moderate to poor activities
as compared to penicillin-G.
The results of antifungal activity are shown in Table 3.
Schiff bases possess moderate to poor activities (19.75–
44.44%) against C. albicans while 2-azetidinone 5f showed
good activity (56.03%) against C. albicans. The remaining 2-
azetidinone derivatives exhibited moderate to poor activities
as compared to amphotericine-B.
4. Conclusions
 Compound containing chloro and methoxy group showed
good antimicrobial activity in most of cases.
 2-Azetidinone derivatives were found active than Schiff
base derivatives.
 Compound containing 4-dimethylamino and 2-hydroxy-4-
diethylamino groups were found inactive against bacterial
species.
Synthesis and antimicrobial activity of Schiff bases and 2-azetidinones derived from quinazolin-4(3H)-one 411 Compound 5f which containing 4-chloro group showed
good antifungal activity with potency of 56.03% against
C. albicans.
 Schiff bases as well as 2-azetidinones possessed moderate to
poor antifungal activity except compound 5f.Acknowledgments
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